A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
NCT ID: NCT07136545
Last Updated: 2025-09-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-08-01
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with pembrolizumab in patients with platinum-refractory recurrent/metastatic HNSCC. The trial consists of two phases: the dose-escalation phase (I) and the dose-expansion phase (II).
Subjects will receive a weekly single dose of HCB101 IV infusion over 60 (±10) minutes on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab (200 mg IV day 1; given every 21 days) until unacceptable AE(s), radiographic or clinically documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study whichever occurs first.
Subjects will receive a weekly single dose of HCB101 IV infusion over 60 (±10) minutes on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab (200 mg IV day 1; given every 21 days) until unacceptable AE(s), radiographic or clinically documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study whichever occurs first.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
NCT05814666
HNSCC
TERMINATED
PHASE2
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
NCT06894459
Head and Neck Cancers
NOT_YET_RECRUITING
PHASE2
Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II
NCT07310771
Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)
NOT_YET_RECRUITING
PHASE2
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05668858
Squamous Cell Carcinoma of Head and Neck
RECRUITING
PHASE1/PHASE2
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258
Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Hypopharyngeal Squamous Cell Carcinoma
+12 more
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HNSCC
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCB101+Pembrolizumab
Group Type
EXPERIMENTAL
HCB101
Intervention Type
DRUG
QW
Pembrolizumab
Intervention Type
DRUG
200 mg IV on Day 1, cycled every 21 days;
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HCB101
QW
Intervention Type
DRUG
Pembrolizumab
200 mg IV on Day 1, cycled every 21 days;
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1\. Subjects are able to understand and willing to provide signed informed consent as described in protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, including study visits and study-related procedures.
* 2\. Male and female subjects of ≥18 years of age, inclusive, at the time of signing the informed consent.
* 3\. With histologically/cytologically confirmed diagnosis of HNSCC
* 4\. With progression after 1st cisplatin based therapy for R/M HNSCC or within 6 months after cisplatin based CCRT
* 5\. Must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
* 6\. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at Screening.
* 7\. Have a life expectancy of ≥12 weeks (according to the Investigator's judgment).
* 8\. Have adequate organ function, as indicated by the following laboratory parameters in below (had not received a blood transfusion, apheresis infusion, erythropoietin, granulocyte colony-stimulating factor, and other relevant medical support within 14 days prior to the administration of the first dose of study intervention).
* a) Absolute neutrophil count ≥1.5 × 109/L
* b) Platelets ≥75 × 109/L
* c) Hemoglobin ≥9.5 g/dL
* d) Total bilirubin ≤1.5 × upper limit of normal (ULN), \<3.0 × ULN if known Gilbert's disease
* e) Alanine aminotransferase and aspartate aminotransferase ≤3× ULN and ≤5× ULN for subject with liver metastasis
* f) Creatinine clearance ≥50 mL/min (using Cockcroft Gault equation)
* g) Coagulation: International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5× ULN (The INR applies only to subjects who do not receive therapeutic anticoagulation). For subjects receiving therapeutic anticoagulation, the INR should be within the therapeutic range for the intended use of the anticoagulants.)
* 9\. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during the Screening Period (within 7 days prior to the first dose of the study intervention).
* 2\. Male and female subjects of ≥18 years of age, inclusive, at the time of signing the informed consent.
* 3\. With histologically/cytologically confirmed diagnosis of HNSCC
* 4\. With progression after 1st cisplatin based therapy for R/M HNSCC or within 6 months after cisplatin based CCRT
* 5\. Must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
* 6\. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at Screening.
* 7\. Have a life expectancy of ≥12 weeks (according to the Investigator's judgment).
* 8\. Have adequate organ function, as indicated by the following laboratory parameters in below (had not received a blood transfusion, apheresis infusion, erythropoietin, granulocyte colony-stimulating factor, and other relevant medical support within 14 days prior to the administration of the first dose of study intervention).
* a) Absolute neutrophil count ≥1.5 × 109/L
* b) Platelets ≥75 × 109/L
* c) Hemoglobin ≥9.5 g/dL
* d) Total bilirubin ≤1.5 × upper limit of normal (ULN), \<3.0 × ULN if known Gilbert's disease
* e) Alanine aminotransferase and aspartate aminotransferase ≤3× ULN and ≤5× ULN for subject with liver metastasis
* f) Creatinine clearance ≥50 mL/min (using Cockcroft Gault equation)
* g) Coagulation: International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5× ULN (The INR applies only to subjects who do not receive therapeutic anticoagulation). For subjects receiving therapeutic anticoagulation, the INR should be within the therapeutic range for the intended use of the anticoagulants.)
* 9\. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during the Screening Period (within 7 days prior to the first dose of the study intervention).
Exclusion Criteria
* 1\. Medical Conditions:
* a) With a known history of hypersensitivity to any components of the study intervention.
* b) Subjects who have other malignancies requiring treatment within 2 years prior to the first dose of study intervention will be excluded, except for radically treated locally curable basal or squamous cell skin cancer and other malignancies that have been treated with no relapse within 2 years.
* c) Primary tumor in the central nervous system (CNS), or active or untreated CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate, provided they are clinically stable for at least 28 days and have no evidence of new or enlarging brain metastases and no requirements for high-dose corticosteroids 14 days prior to dosing with study intervention. Subjects on low-dose corticosteroids (\<20 mg prednisolone or equivalent per day) may participate.
* d) Clinically significant cardiovascular condition, including 1)History of congestive heart failure (New York Heart Association Class \>2), with only heart failure with preserved ejection fraction (HFpEF) included; 2)History of unstable angina within 6 months prior to the first dose of study intervention; 3)New-onset angina or myocardial infarction within 6 months prior to the first dose of study intervention; 4)New-onset of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia within 6 months prior to the first dose of study intervention and still in unstable condition and requiring treatment or intervention. History of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia will be allowed, provided the condition is stably controlled.
* e) History or presence of an abnormal ECG that, in the Investigator's opinion, is clinically meaningful (including QT interval corrected for heart rate using Fridericia's correction \[QTcF\] \>470 msec at Screening, pacemaker installation, or previous diagnosis of congenital long QT syndrome).
* f) Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia (Note: subjects with chronic Grade 2 toxicities which are well managed and stable may be eligible per the discretion of the Investigator, Grade 2 chemotherapy-induced neuropathy.)
* g) With known inherited or acquired bleeding disorders or bleeding diathesis.
* h) With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.
* i) With active autoimmune diseases that required systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within the past two years are excluded. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroids for adrenal or pituitary insufficiency) is allowed.
* j) With a history of or current non-infectious pneumonitis.
* k) With a history of severe hypersensitivity to monoclonal antibodies.
* 2\. Prior/Concomitant Therapy/Treatment
* a) Subjects who have undergone major surgery or radical radiotherapy within 28 days prior to the first dose of study intervention.
* b) Subjects who have undergone any investigational or approved systemic cancer therapy (including chemotherapy, immunotherapy, hormonal therapy, and herbal/alternative therapies with anti-cancer indications or targeted therapy) within 14 days or 5 half lives, whichever is longer, prior to the first dose of the study intervention.
* c) Subjects who have used herbal medication within 14 days prior to the first dose of the study intervention.
* d) Subjects who are active using of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on a case-by-case basis. There will be no restriction for daily aspirin ≤ 100 mg/QD.
* e) Subjects who have received any treatment targeting the CD47 or SIRPα pathway.
* f) Subjects who have previously received pembrolizumab treatment.
* g) Subjects who have received a live vaccine within 30 days prior to pembrolizumab administration.
* h) Subjects diagnosed with immunodeficiency, receiving systemic steroid therapy, or having received any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab.
* 3\. Participation in another clinical study with an investigational product administered in the last 14 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study intervention. An investigational device was used within 28 days prior to the first dose of study intervention.
* 4\. Reproductive and breastfeeding
* a) Women of reproductive potential who are unable to use effective contraception during treatment and for 4 months after the last dose.
* b) Women who are breastfeeding during treatment and for 4 months after the last dose.
* 5\. Infections:
* a) An uncontrolled acute infection, an active infection requiring systemic treatment, or subjects who have received systemic antibiotics within 7 days prior to the first dose of the study intervention (Note: prophylaxis use of systemic antibiotics treatment for upper tract infection is allowed as long as there is no violation of the requirement of concomitant medications).
* b) Known history of human immunodeficiency virus (HIV) infection.
* c) Active tuberculosis.
* d) Known history of hepatitis B or hepatitis C infection. Subjects who test positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody.
* 6\. Any other medical (e.g., Child-Pugh class B or C, pulmonary, metabolic, congenital, endocrinal or CNS disease, etc.), psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
* a) With a known history of hypersensitivity to any components of the study intervention.
* b) Subjects who have other malignancies requiring treatment within 2 years prior to the first dose of study intervention will be excluded, except for radically treated locally curable basal or squamous cell skin cancer and other malignancies that have been treated with no relapse within 2 years.
* c) Primary tumor in the central nervous system (CNS), or active or untreated CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate, provided they are clinically stable for at least 28 days and have no evidence of new or enlarging brain metastases and no requirements for high-dose corticosteroids 14 days prior to dosing with study intervention. Subjects on low-dose corticosteroids (\<20 mg prednisolone or equivalent per day) may participate.
* d) Clinically significant cardiovascular condition, including 1)History of congestive heart failure (New York Heart Association Class \>2), with only heart failure with preserved ejection fraction (HFpEF) included; 2)History of unstable angina within 6 months prior to the first dose of study intervention; 3)New-onset angina or myocardial infarction within 6 months prior to the first dose of study intervention; 4)New-onset of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia within 6 months prior to the first dose of study intervention and still in unstable condition and requiring treatment or intervention. History of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia will be allowed, provided the condition is stably controlled.
* e) History or presence of an abnormal ECG that, in the Investigator's opinion, is clinically meaningful (including QT interval corrected for heart rate using Fridericia's correction \[QTcF\] \>470 msec at Screening, pacemaker installation, or previous diagnosis of congenital long QT syndrome).
* f) Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia (Note: subjects with chronic Grade 2 toxicities which are well managed and stable may be eligible per the discretion of the Investigator, Grade 2 chemotherapy-induced neuropathy.)
* g) With known inherited or acquired bleeding disorders or bleeding diathesis.
* h) With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.
* i) With active autoimmune diseases that required systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within the past two years are excluded. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroids for adrenal or pituitary insufficiency) is allowed.
* j) With a history of or current non-infectious pneumonitis.
* k) With a history of severe hypersensitivity to monoclonal antibodies.
* 2\. Prior/Concomitant Therapy/Treatment
* a) Subjects who have undergone major surgery or radical radiotherapy within 28 days prior to the first dose of study intervention.
* b) Subjects who have undergone any investigational or approved systemic cancer therapy (including chemotherapy, immunotherapy, hormonal therapy, and herbal/alternative therapies with anti-cancer indications or targeted therapy) within 14 days or 5 half lives, whichever is longer, prior to the first dose of the study intervention.
* c) Subjects who have used herbal medication within 14 days prior to the first dose of the study intervention.
* d) Subjects who are active using of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on a case-by-case basis. There will be no restriction for daily aspirin ≤ 100 mg/QD.
* e) Subjects who have received any treatment targeting the CD47 or SIRPα pathway.
* f) Subjects who have previously received pembrolizumab treatment.
* g) Subjects who have received a live vaccine within 30 days prior to pembrolizumab administration.
* h) Subjects diagnosed with immunodeficiency, receiving systemic steroid therapy, or having received any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab.
* 3\. Participation in another clinical study with an investigational product administered in the last 14 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study intervention. An investigational device was used within 28 days prior to the first dose of study intervention.
* 4\. Reproductive and breastfeeding
* a) Women of reproductive potential who are unable to use effective contraception during treatment and for 4 months after the last dose.
* b) Women who are breastfeeding during treatment and for 4 months after the last dose.
* 5\. Infections:
* a) An uncontrolled acute infection, an active infection requiring systemic treatment, or subjects who have received systemic antibiotics within 7 days prior to the first dose of the study intervention (Note: prophylaxis use of systemic antibiotics treatment for upper tract infection is allowed as long as there is no violation of the requirement of concomitant medications).
* b) Known history of human immunodeficiency virus (HIV) infection.
* c) Active tuberculosis.
* d) Known history of hepatitis B or hepatitis C infection. Subjects who test positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody.
* 6\. Any other medical (e.g., Child-Pugh class B or C, pulmonary, metabolic, congenital, endocrinal or CNS disease, etc.), psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FBD Biologics Limited
INDUSTRY
Sponsor Role
collaborator
National Taiwan University Hospital
OTHER
Sponsor Role
collaborator
Chang Gung Memorial Hospital
OTHER
Sponsor Role
collaborator
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mu-Hsin Chang
Attending Physician
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mu-Hsin Chang
Role: PRINCIPAL_INVESTIGATOR
Taipei Veterans General Hospital, Taiwan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chang-Gung Memorial Hospital(Lin-Kou)
Taoyuan District, Guishan District, Taiwan
Site Status
RECRUITING
National Taiwan University Hospital
Taipei, Taipei city, Taiwan
Site Status
RECRUITING
Taipei Veterans General Hospital
Taipei, taipei city, Taiwan
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-01-015B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
NCT05420948
RECRUITING
PHASE2
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
NCT05446467
RECRUITING
PHASE2
SHR-1701 in Patients With Recurrent/Metastatic Scchn
NCT04650633
UNKNOWN
PHASE2
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06714266
NOT_YET_RECRUITING
PHASE2
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
NCT05726370
RECRUITING
PHASE2
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06668961
RECRUITING
PHASE2
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NCT05283226
RECRUITING
PHASE2
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
NCT06308913
RECRUITING
EARLY_PHASE1
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
NCT02358031
COMPLETED
PHASE3
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
NCT02775812
COMPLETED
PHASE1
Study of SCB01A in Patient With Head and Neck Cancer
NCT02488629
TERMINATED
PHASE2
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
NCT06194656
RECRUITING
PHASE2
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)
NCT01326559
COMPLETED
PHASE2
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
NCT06100497
RECRUITING
PHASE2
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
NCT05816785
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
NCT04146181
UNKNOWN
PHASE2
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
NCT05941338
RECRUITING
PHASE2
Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma
NCT05476965
UNKNOWN
PHASE2
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918
ACTIVE_NOT_RECRUITING
PHASE3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06589804
RECRUITING
PHASE3
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
NCT06597565
RECRUITING
PHASE2
Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)
NCT05136768
UNKNOWN
PHASE2
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
NCT03712397
COMPLETED
PHASE2
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
NCT06236425
ACTIVE_NOT_RECRUITING
PHASE1
Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma
NCT04107103
COMPLETED
PHASE2